Zydus Lifesciences shares in focus after FDA approval for prostate cancer drug
Zydus Lifesciences shares will be in focus on Wednesday after the company secured final approval from the US Food and Drug Administration (USFDA) to manufacture a generic version of Apalutamide tablets, used to treat prostate cancer.
The approval covers Apalutamide tablets of 60 mg strength, the company said in a regulatory filing. The drug will be manufactured at Zydus Lifesciences' SEZ facility in Ahmedabad.
Apalutamide, an androgen receptor inhibitor, is prescribed for patients with metastatic castration-sensitive prostate cancer. It had annual US sales of $1,099.8 million, according to IQVIA MAT January 2025 data.
Last week, Zydus Lifesciences also received USFDA approval to manufacture Eluxadoline tablets (75 mg and 100 mg), used to treat irritable bowel syndrome with diarrhea in adults. These will also be produced at the SEZ facility in Ahmedabad.
Zydus was among the first to file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification for Eluxadoline tablets. This approval grants the company 180 days of shared generic exclusivity for the drug.
Live Events
Zydus Life shares target price
As per Trendlyne data, the average target price of the stock is Rs 1,064, which shows an upside of 18% from the current market prices. The consensus recommendation from 31 analysts for the stock is a 'Hold'.
Technically, the stock's relative strength index (RSI) is at 48. According to Trendlyne, an RSI below 30 is considered oversold, while above 70 indicates overbought conditions. Additionally, the